Bacteriological Testing Market By Testing Method (Culture Based Testing, Molecular Diagnostics, Immunological Methods, Automated Testing Systems); By Application (Food and Beverage Testing, Water and Environmental Testing, Pharmaceutical Testing, Clinical Diagnostics); By Sample Type (Raw Materials, Finished Products, Environmental Swabs, Water Samples); By End User (Food Producers, Water Utilities and Municipal Services, Pharmaceutical Manufacturers, Clinical Laboratories, Contract Testing Laboratories); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Bacteriological Testing Market Size and How Are Rapid Diagnostics Reshaping Clinical Microbiology?  – (Updated On: 24-Aug-2026)

The Global Bacteriological Testing Market was valued at USD 25.40 billion in 2025 and is projected to reach USD 42.97 billion by 2032, expanding at a CAGR of 7.8% during 2026–2032, according to Strategic Market Research.

 

Bacteriological testing is used to find and study bacteria in patient samples, food, water, medicines, and controlled environments. In healthcare, samples such as blood, urine, respiratory fluids, stool, and wound material are examined to identify the bacteria causing an infection. Testing may also show which antibiotics are likely to work, helping doctors choose the most suitable treatment.

 

The transition from culture-only workflows is already visible in U.S. surveillance: CDC FoodNet reported that 78% of bacterial infections in its 2024 analysis were diagnosed using culture-independent diagnostic tests, compared with 47% during 2016–2018. WHO's 2025 global AMR surveillance report drew on more than 23 million bacteriologically confirmed infection episodes, showing the scale at which organism identification and susceptibility data are now being generated internationally. This shift is expanding the commercial role of rapid microbiology testing across clinical and public-health laboratories.

 

FDA cleared Hologic's Panther Fusion GI Bacterial Assay in September 2025, Cepheid's Xpert GI Panel in January 2026, and QIAGEN's QIAstat-Dx gastrointestinal panels for use with the QIAstat-Dx Rise system in March 2026. These tests help laboratories quickly find bacteria that can cause stomach and intestinal infections. In July 2026, FDA also cleared bioMérieux's updated VITEK REVEAL system to automatically test which antibiotics are likely to work against bacteria found in positive blood cultures. In August 2026, QIAGEN received clearance for its QIAstat-Dx BCID GPF Plus AMR Panel, which can identify infection-causing organisms and detect genetic signs that the organisms may resist certain antibiotics.

 

This is clinically important in bloodstream infection pathways because CDC estimates at least 1.7 million U.S. adults develop sepsis each year. Pipeline activity also remains active: bioMérieux submitted updated BIOFIRE gastrointestinal panels for FDA review in June 2026, while QIAGEN has identified complicated-UTI and pneumonia panels among its QIAstat-Dx development programs. Wider adoption of antimicrobial resistance testing is therefore connecting rapid organism identification with treatment-selection decisions.

 

Bacteriological Testing Market Insights Across Technologies, Applications, Sample Types and End Users

By Testing Method

• Culture-Based Testing: Leads with a 33% share because viable isolates remain important for confirmation, phenotypic AST, outbreak investigation, and downstream characterization.

• Molecular Diagnostics: Holds 29% and records the fastest testing-method CAGR of 9.4% as multiplex PCR and other nucleic-acid assays shorten pathogen-identification workflows.

• Immunological Methods: Represents 20% and remains relevant for rapid antigen-based screening in clinical, food, and environmental applications.

• Automated Testing Systems: Accounts for 18% and expands at 9.3% as laboratories automate blood culture, ID/AST, specimen processing, and result interpretation.

 

By Application

• Food and Beverage Testing: Leads with 34% through routine pathogen, environmental, ingredient, and finished-product testing.

• Water and Environmental Testing: Accounts for 24% through repeated testing for coliforms, E. coli, and other bacterial indicators.

• Pharmaceutical Testing: Represents 19% and expands at 8.4% through sterility, bioburden, environmental monitoring, and microbial quality-control workflows.

• Clinical Diagnostics: Holds 23% and expands at 8.4% as culture, multiplex PCR, rapid AST, MALDI-TOF, and sequencing become increasingly connected.

 

By Sample Type

• Raw Materials: Leads with 28% because incoming ingredients and production inputs are routinely screened before manufacturing.

• Finished Products: Accounts for 27% through batch-release, quality-control, shelf-life, and contamination testing.

• Environmental Swabs: Holds 20% and records the fastest sample-type CAGR of 8.6% as contamination-control programs intensify in controlled facilities.

• Water Samples: Represents 25% and grows at 8.1% across municipal, industrial, pharmaceutical, and environmental monitoring.

 

By End User

• Food Producers: Lead with 28% due to testing across ingredients, processing environments, equipment, and finished products.

• Water Utilities and Municipal Services: Hold 18% through recurring microbiological water-quality testing.

• Pharmaceutical Manufacturers: Account for 18% and expand at 8.3% through quality-control and contamination-monitoring requirements.

• Clinical Laboratories: Represent 21% and expand at 8.4% as rapid molecular and automated susceptibility platforms broaden microbiology menus.

• Contract Testing Laboratories: Hold 15% and record the fastest end-user CAGR of 8.5% as specialized microbiology, sequencing, and outsourced QC testing expand.

 

Innovative Testing Technologies Driving the Bacteriological Testing Market Through 2032

Culture-based testing accounted for 33% of the market, representing USD 8.38 billion in 2025, and is projected to expand at a CAGR of 5.8% during 2026–2032. Culture maintains the largest share because it produces viable bacterial isolates that can be used for organism confirmation, minimum inhibitory concentration testing, serotyping, sequencing, and public-health investigation. Automated systems have made culture more scalable rather than obsolete. For example, BD's BACTEC platform and bioMérieux's BACT/ALERT systems automate blood culture testing while preserving isolates for downstream identification and AST. The 2024 BACTEC bottle shortage also demonstrated how clinically embedded culture remains: affected BACTEC hospitals recorded a 27.4% reduction in blood-culture rates during the shortage period.

Molecular diagnostics, including PCR and isothermal amplification, represented 29% of the market, equivalent to USD 7.37 billion in 2025, and are projected to expand at a CAGR of 9.4%. Their faster growth reflects the clinical value of detecting bacterial nucleic acids without waiting for conventional colony isolation in every case. Companies such as Cepheid, Hologic, and QIAGEN have expanded multiplex gastrointestinal and bloodstream-infection menus around existing automated platforms. FDA's January 2026 clearance of Cepheid's Xpert GI Panel, September 2025 clearance of Hologic's Panther Fusion GI Bacterial Assay, and 2026 QIAstat-Dx clearances show how bacterial targets are moving into consolidated syndromic-testing workflows.

Immunological methods accounted for 20% of the market, representing USD 5.08 billion in 2025, and are expected to expand at a CAGR of 7.1%. ELISA, lateral-flow, and other antibody- or antigen-based formats remain commercially relevant where laboratories need simpler workflows, relatively fast screening, or lower instrument requirements. Their role is particularly important in food, environmental, and selected clinical screening applications, although confirmatory culture or molecular testing may still be needed when strain-level identification or susceptibility information is required.

Automated testing systems represented 18% of the market, valued at USD 4.57 billion in 2025, and are projected to expand at a CAGR of 9.3%. Automation is moving beyond incubation into organism identification, MIC interpretation, rapid phenotypic AST, robotic specimen processing, and laboratory-information-system connectivity. For instance, bioMérieux's VITEK REVEAL performs automated growth-based susceptibility testing directly from positive blood cultures, while Q-Linea's ASTar platform uses automated rapid AST from positive cultures. FDA cleared an expanded ASTar BC G- Kit in April 2026 and the updated VITEK REVEAL system in July 2026, broadening the commercially available rapid-AST category.

 

Major Application Segments Driving the Bacteriological Testing Market

Food and beverage testing accounted for 34% of the market, representing USD 8.64 billion in 2025, and is projected to expand at a CAGR of 7.5%. Its leading position reflects repeated testing across ingredients, production environments, processing equipment, and finished foods for Salmonella, Listeria, pathogenic E. coli, Campylobacter, and other bacterial hazards. Product development is shifting part of this workload toward validated PCR methods. Thermo Fisher Scientific's SureTect portfolio, for example, includes PCR assays for Salmonella, Listeria, E. coli O157, STEC, Campylobacter, Cronobacter, and other foodborne targets across food and environmental samples, strengthening the role of rapid methods within the wider food safety testing market.

Water and environmental testing represented 24% of the market, equivalent to USD 6.10 billion in 2025, and is projected to expand at a CAGR of 7.1%. These workflows are recurring because public-water, wastewater, industrial, recreational-water, and facility-monitoring programs continually collect samples rather than testing only during outbreaks. IDEXX's Colilert illustrates the commercial profile of this segment by simultaneously detecting or quantifying total coliforms and E. coli in a 24-hour workflow for water laboratories.

Pharmaceutical testing accounted for 19% of the market, representing USD 4.83 billion in 2025, and is projected to expand at a CAGR of 8.4%. Pharmaceutical and biotechnology manufacturers use bacteriological methods for bioburden, microbial limits, sterility, environmental monitoring, organism identification, and production-quality investigations. Charles River's Celsis platforms illustrate the movement toward faster QC workflows by using ATP-based microbial detection to shorten microbial-limits and sterility testing compared with conventional compendial timelines. bioMérieux has also extended rapid molecular testing into pharmaceutical quality control through its BIOFIRE SPOTFIRE platform for mycoplasma testing.

Clinical diagnostics represented 23% of the market, equivalent to USD 5.84 billion in 2025, and are projected to expand at a CAGR of 8.4%. Clinical bacteriology is commercially attractive because an individual infection can generate several sequential tests: culture, identification, resistance-marker detection, phenotypic AST, and sometimes sequencing. Recent clinical product activity from QIAGEN, bioMérieux, Cepheid, Hologic, and BD reflects competition for this connected workflow rather than for a single stand-alone assay. QIAGEN's August 2026 FDA-cleared BCID GPF Plus AMR Panel is an example, combining detection of bacterial and fungal targets with 10 genetic AMR markers from positive blood cultures in about one hour. These faster workflows also increase the strategic value of sepsis diagnostics when treatment decisions must be made quickly.

 

Sample Types Define Workflow Design and Technology Selection in the Bacteriological Testing Market

Raw materials accounted for 28% of the market, representing USD 7.11 billion in 2025, and are projected to expand at a CAGR of 7.1%. Incoming raw ingredients are tested before they enter food, beverage, pharmaceutical, biotechnology, and other controlled manufacturing processes. Their leading share reflects the commercial value of identifying contamination before it propagates through production, where later corrective action becomes more expensive and disruptive.

Finished products represented 27% of the market, equivalent to USD 6.86 billion in 2025, and are projected to expand at a CAGR of 7.6%. Finished-product testing supports batch release, microbiological quality, shelf-life programs, sterility assessment, and investigation of out-of-specification findings. Rapid microbial platforms are particularly relevant where holding finished inventory during conventional incubation affects production cycles. Charles River's Celsis technology is positioned around this operational issue by accelerating microbial-limit and sterility readouts for pharmaceutical and consumer-product QC laboratories.

Environmental swabs accounted for 20% of the market, representing USD 5.08 billion in 2025, and are forecast to record the fastest sample-type CAGR at 8.6%. Swabbing production surfaces, cleanrooms, food-processing equipment, hospital environments, and controlled manufacturing areas can identify contamination before it reaches products or patients. Molecular systems are increasingly being validated for these matrices; Thermo Fisher's SureTect Listeria assays, for instance, are designed for both foods and environmental samples.

Water samples represented 25% of the market, equivalent to USD 6.35 billion in 2025, and are projected to expand at a CAGR of 8.1%. Testing covers drinking water, wastewater, source water, process water, pharmaceutical water systems, and environmental surveillance. The segment uses a combination of membrane filtration, enzyme-substrate detection, culture, quantitative methods, and increasingly molecular assays. Products such as IDEXX Colilert combine standardized reagent formats with coliform and E. coli measurement, supporting routine high-volume water microbiology.

 

How Hospitals, Laboratories, Manufacturers, and Public-Health Agencies Are Driving Bacteriological Testing Demand

Food producers accounted for 28% of the market, representing USD 7.11 billion in 2025, and are projected to expand at a CAGR of 7.2%. Their bacteriology programs cover raw materials, production environments, pathogen screening, sanitation verification, and finished products. Product portfolios from Thermo Fisher Scientific and bioMérieux support the shift toward in-house PCR and automated microbiology where rapid release decisions are commercially important. Thermo Fisher's SureTect platform, for example, provides molecular workflows for several major foodborne bacterial targets.

Water utilities and municipal services represented 18% of the market, equivalent to USD 4.57 billion in 2025, and are projected to grow at a 6.8% CAGR. The U.S. alone had 147,252 active public water systems in 2024, creating a large recurring testing base. EPA rules require routine coliform sampling and E. coli analysis following positive results, sustaining demand for media, consumables and quantification platforms. IDEXX is strongly positioned through standardized coliform and E. coli testing workflows.

Pharmaceutical manufacturers accounted for 18% of the market, representing USD 4.57 billion in 2025, and are projected to expand at an 8.3% CAGR. FDA's FY2025 pharmaceutical-quality inventory covered 5,953 manufacturing sites globally, illustrating the scale of regulated QC demand. Microbial limits, environmental monitoring, sterility and bioburden testing are embedded throughout production rather than confined to final release. Charles River and bioMérieux are consequently positioning rapid microbial methods around faster contamination detection and shorter batch-release cycles.

Clinical laboratories represented 21% of the market, equivalent to USD 5.33 billion in 2025, and are projected to expand at a CAGR of 8.4%. Hospitals and reference laboratories are integrating blood culture, MALDI-TOF, automated ID/AST, multiplex PCR, resistance-gene analysis, and sequencing according to specimen type and clinical urgency. Providers such as BD, Cepheid, bioMérieux, and QIAGEN compete across different stages of this workflow.

Contract testing laboratories accounted for 15% of the market, representing USD 3.81 billion in 2025, and are projected to record the fastest end-user CAGR at 8.5%. Outsourcing gains relevance when clients need sequencing, unusual-organism identification, environmental monitoring or validated pharmaceutical microbiology without funding every platform internally. Scale is already substantial: Eurofins performs more than 450 million tests annually across over 950 laboratories in 57 countries. This network model supports high-throughput testing while favoring providers that standardize methods, turnaround times and reporting across multiple sites.

 

Regional Market Dynamics Across North America, Europe, Asia-Pacific, Latin America and the Middle East & Africa

North America accounted for 36% of the Bacteriological Testing Market, representing USD 9.14 billion in 2025, and is projected to expand at a CAGR of 7.0%. The region combines large hospital and reference-laboratory infrastructure with extensive molecular-testing and AMR-surveillance capacity. CDC's AR Laboratory Network has performed more than 1.5 million tests through the end of 2025, while the broader U.S. system includes roughly 330,000 CLIA-certified laboratories. Recent product activity from Hologic, Cepheid, QIAGEN, bioMérieux, and Q-Linea also shows that the U.S. remains an important launch market for multiplex bacterial panels and rapid AST.

Europe represented 28% of the market, equivalent to USD 7.11 billion in 2025, and is projected to expand at a CAGR of 7.2%. The region combines hospital microbiology with centralized specialist and reference services. In England, UKHSA's Bacteriology Reference Department performs specialist bacterial characterization and susceptibility testing for samples received from NHS, public-health, commercial, and international laboratories. UKHSA's AMR module of the Second Generation Surveillance System receives voluntary data from approximately 98% of hospital microbiology laboratories in England, creating an extensive information base for susceptibility surveillance. Companies such as bioMérieux and QIAGEN also maintain broad European portfolios spanning culture, ID/AST, molecular panels, and bloodstream-infection testing.

Asia-Pacific accounted for 24% of the market, representing USD 6.10 billion in 2025, and is projected to record the fastest regional CAGR at 9.4%. The region combines highly automated diagnostic systems in Japan, Australia, South Korea, Singapore, China, and major Indian centers with laboratories that still rely heavily on culture and manual AST. WHO reported in 2026 that one in six bacterial infections globally was resistant to antibiotics, reinforcing the role of laboratory identification and susceptibility testing across countries with very different diagnostic infrastructure. Product activity is also broadening; QIAGEN, for example, continues to expand QIAstat-Dx registrations and menus in Asia-Pacific markets while molecular, MALDI-TOF, and automated AST capacity expands in tertiary centers.

Latin America represented 7% of the Bacteriological Testing Market, equivalent to USD 1.78 billion in 2025, and is projected to expand at a CAGR of 8.0%. Regional development is closely linked to public-health and AMR laboratory networks. PAHO's ReLAVRA+ network had expanded to 33 countries by 2025 and supports standardized resistance detection, external quality assessment, isolate-level surveillance, data sharing, and genomic capability. These initiatives create a market for bacterial identification, AST, reference testing, sequencing, informatics, and laboratory quality-control products.

The Middle East & Africa accounted for 5% of the market, representing USD 1.27 billion in 2025, and is projected to expand at a CAGR of 8.4%. Commercial development is uneven because advanced automated microbiology is concentrated in national laboratories, major private networks, and tertiary hospitals, while many decentralized facilities continue to depend on culture and manual susceptibility methods. WHO reported that one in five bacterial infections in the African Region was resistant to antibiotics in 2023, making reliable bacterial identification and AST particularly important as countries strengthen surveillance systems and laboratory networks.

 

Leading Innovators and Portfolio Strategies Shaping the Bacteriological Testing Market

Competition in the Bacteriological Testing Market is defined by breadth of microbiology workflow, time-to-result, automation, assay menu, organism coverage, resistance characterization, recurring consumables, laboratory connectivity, and the ability to serve multiple testing environments. Clinical competitors increasingly connect culture, organism identification, molecular testing, and AST, while food, water, and pharmaceutical suppliers compete through validated rapid methods, workflow simplification, and specialized quality-control portfolios.

Becton, Dickinson and Company
BD's bacteriological testing portfolio is centered on microbiology infrastructure, including BACTEC blood-culture systems, microbiology consumables, organism identification and susceptibility products, automation, and BD MAX molecular diagnostics. BACTEC gives BD a strong position in hospital bloodstream-infection workflows where bottles generate recurring consumable use around an installed analyzer base. BD MAX extends the portfolio into automated molecular testing. BD reported USD 1.838 billion in Diagnostic Solutions revenue in fiscal 2025, with lower BACTEC sales following normalization after the supply disruption partly offset by continued MAX IVD growth.

bioMérieux
bioMérieux operates across several bacteriology stages through BACT/ALERT blood culture, VITEK identification and AST, VITEK REVEAL rapid susceptibility testing, BIOFIRE syndromic molecular panels, and industrial microbiology solutions. The July 2026 FDA clearance of the updated VITEK REVEAL system strengthened its rapid-AST position for Gram-negative organisms from positive blood cultures. The company is also advancing its molecular menu: in June 2026 it submitted the BIOFIRE FILMARRAY GI1.1 and GI1.1 Mid panels for FDA 510(k) review, clearly placing these products in the regulatory pipeline rather than describing them as cleared.

Danaher / Cepheid
Cepheid, part of Danaher's Diagnostics segment, competes through the GeneXpert cartridge-based molecular platform. The system integrates sample preparation, nucleic-acid amplification, and detection with relatively limited hands-on processing, allowing laboratories to add new infectious-disease assays to an existing installed platform. FDA cleared the Xpert GI Panel in January 2026 for multiplex gastrointestinal testing. Danaher's Diagnostics segment generated USD 9.94 billion in 2025, with 89% of revenue classified as recurring, illustrating the commercial importance of assay and consumable pull-through around installed diagnostic systems.

QIAGEN
QIAGEN's QIAstat-Dx platform combines cartridge-based sample preparation, molecular amplification, and result interpretation across syndromic infectious-disease panels. FDA cleared gastrointestinal panels for QIAstat-Dx Rise in March 2026 and cleared the BCID GPF Plus AMR Panel in August 2026. The bloodstream panel detects 20 pathogen targets plus a broad Gram-negative target and 10 genetic AMR markers from positive blood cultures in about one hour. QIAGEN also has additional QIAstat-Dx development programs for complicated urinary tract infection and pneumonia, while its Gram-negative bloodstream-infection panel was undergoing U.S. regulatory review as of the latest company update.

Hologic
Hologic competes in molecular bacteriology through the Panther Fusion platform. FDA cleared its GI Bacterial and GI Expanded Bacterial assays in September 2025. The standard bacterial assay detects nucleic acids from Salmonella, Shigella/enteroinvasive E. coli, Campylobacter, and Shiga-toxin-producing E. coli. The portfolio is differentiated by the ability to add gastrointestinal bacterial testing to the broader Panther Fusion molecular workflow rather than introducing a separate analyzer exclusively for bacteriology.

Q-Linea
Q-Linea is focused more narrowly on rapid phenotypic antimicrobial susceptibility testing. FDA cleared the ASTar BC G- Kit and ASTar Instrument in April 2024 and an expanded ASTar BC G- Kit in April 2026. The newer submission added antimicrobial agents and additional organism-antimicrobial combinations while retaining automated direct-from-positive-blood-culture testing. This gives Q-Linea a differentiated position between conventional overnight AST and molecular resistance-gene testing because the platform reports phenotypic susceptibility rather than inferring it solely from genotype.

Thermo Fisher Scientific
Thermo Fisher Scientific has a broad bacteriological portfolio spanning culture media, molecular systems, and food microbiology. Its SureTect PCR line includes assays for Salmonella, Listeria, E. coli O157, STEC, Campylobacter, Cronobacter, and other bacterial targets in food and environmental matrices. This gives Thermo Fisher relevance particularly in the food and beverage and environmental portions of the market, where laboratories may combine conventional enrichment with high-throughput PCR confirmation.

IDEXX Laboratories
IDEXX has a focused position in bacteriological water testing through products including Colilert and Quanti-Tray workflows. Colilert simultaneously detects or quantifies total coliforms and E. coli with a 24-hour incubation workflow and is used across drinking water, wastewater, and source-water testing. Its standardized reagent format and low hands-on time make the portfolio particularly relevant to utilities and laboratories processing recurring water samples.

Charles River Laboratories
Charles River participates in pharmaceutical and industrial microbiology through rapid microbial-detection systems, reagents, and QC services. The Celsis Accel platform uses ATP bioluminescence to shorten microbial-limits testing to approximately 24–36 hours and sterility testing to six days in its specified workflows. The platform is positioned around faster manufacturing-quality decisions rather than clinical pathogen diagnosis, giving Charles River a differentiated role in the pharmaceutical-testing segment.

 

Innovating Bacteriological Testing: Market Forces, Technology Shifts, and Growth Pathways Through 2032

The Bacteriological Testing Market is developing toward a connected multi-technology model rather than a complete replacement of culture. Molecular assays provide faster frontline pathogen detection, culture preserves viable isolates, MALDI-TOF shortens organism identification after growth, rapid AST reduces the interval to phenotypic susceptibility information, and sequencing supports unusual-pathogen identification and surveillance. Each technology therefore captures a different stage of the same diagnostic or quality-control pathway.

The 9.4% CAGR supplied for molecular diagnostics and 9.3% CAGR for automated testing systems reflect this transition toward higher-value, software-enabled testing. Recent FDA clearances from Hologic, Cepheid, QIAGEN, bioMérieux, and Q-Linea show that the competitive frontier is moving toward consolidated panels and faster susceptibility information rather than basic organism detection alone. Research technologies such as AI-assisted microcolony imaging, microfluidic chips, phage-activated sensors, nanoparticle enrichment, and host-depleted sequencing could further shorten workflows, but commercial adoption will depend on reproducibility, regulatory validation, clinical utility, and cost.

AMR surveillance provides another durable testing requirement. WHO's surveillance analysis is already based on more than 23 million confirmed infection episodes, and the U.S. AR Laboratory Network has generated more than 664,000 whole-genome sequences through the end of 2025. These data position bacteriological testing not only as an individual diagnostic event but also as infrastructure for treatment selection, antimicrobial stewardship, outbreak investigation, pharmaceutical development, food safety, and population-level resistance surveillance.

 

Bacteriological Testing Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 25.40 Billion
Revenue Forecast in 2032	USD 42.97 Billion
Overall Growth Rate	CAGR of 7.8% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Billion, CAGR (2026–2032)
Segmentation	By Testing Method, By Application, By Sample Type, By End User, and By Geography
By Testing Method	Culture Based Testing, Molecular Diagnostics, Immunological Methods, Automated Testing Systems
By Application	Food and Beverage Testing, Water and Environmental Testing, Pharmaceutical Testing, Clinical Diagnostics
By Sample Type	Raw Materials, Finished Products, Environmental Swabs, Water Samples
By End User	Food Producers, Water Utilities and Municipal Services, Pharmaceutical Manufacturers, Clinical Laboratories, Contract Testing Laboratories
By Geography	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country Scope	United States, Canada, Mexico, United Kingdom, Germany, France, Italy, Spain, Netherlands, Sweden, Norway, China, Japan, India, South Korea, Australia, New Zealand, Brazil, Argentina, Saudi Arabia, United Arab Emirates, South Africa, and Other Countries
Market Drivers	Expansion of rapid molecular diagnostics, rising antimicrobial-resistance surveillance, adoption of automated identification and susceptibility systems, recurring food and water safety testing, pharmaceutical microbiology requirements, and growing clinical use of multiplex bacterial panels
Customization Option	Available upon request